[1]
|
C. Baldamus, S. Krivoshiev, M. Wolf-Pflugmann, M. Siebert-Weigel, R. Koytchev and A. Bronn, “Long-Term Safety and Tolerability of Epoetin Zeta, Administered Intravenously, for Maintenance Treatment of Renal Anemia,” Advances in Therapy, Vol. 25, No. 11, 2008, pp. 1215-1228. doi:10.1007/s12325-008-0111-1
|
[2]
|
S. Krivoshiev, V. V. Todorov, J. Manitius, S. Czekalski, P. Scigalla and R. Koytchev, “Comparison of the Therapeutic Effects of Epoetin Zeta and Epoetin Alpha in the Correction of Renal Anaemia,” Current Medical Research and Opinion, Vol. 24, No. 5, 2008, pp. 1407-1415.
doi:10.1185/030079908X297402
|
[3]
|
H. Schellekens, “Assessing the Bioequivalence of Biosimilars the Retacrit Case,” Drug Discovery Today, Vol. 14, No. 9-10, 2009, pp. 495-499.
doi:10.1016/j.drudis.2009.02.003
|
[4]
|
V. Wizemann, B. Rutkowski, C. Baldamus, P. Scigalla and R. Koytchev, “Comparison of the Therapeutic Effects of Epoetin Zeta to Epoetin Alfa in the Maintenance Phase of Renal Anaemia Treatment,” Current Medical Research and Opinion, Vol. 24, No. 3, 2008, pp. 625-637.
doi:10.1185/030079908X273264
|
[5]
|
G. Lonnemann and E. Wrenger, “Biosimilar Epoetin Zeta in Nephrology—A Single-Dialysis Center Experience,” Clinical Nephrology, Vol. 75, No. 1, 2011, pp. 59-62.
|
[6]
|
E. Orazi, “[Switch from Darbepoetin-Alpha to Epoetin- Alpha: Cost and Efficacy Comparison for Haemodialytic Patients over One Year Follow-Up in a Single Centre],” G Ital Nefrol, Vol. 25, No. 2, 2008, pp. 223-226.
|
[7]
|
F. Ranchon, S. Hedoux, M. Laville, D. Fouque, E. Decullier, F. Chapuis and L. Huot, “[Direct Medical Cost of Eryt-hropoiesis-Stimulating Agents in Anaemia Treatment of Chronic Renal Failure Patient: A Literature Review],” Nephrologie & Therapeutique, Vol. 6, No. 2, 2010, pp. 97-104. doi:10.1016/j.nephro.2009.10.004
|
[8]
|
D. Goldsmith, “2009: A Requiem for rHuEPOs--But Should We Nail down the Coffin in 2010?” inical Journal of the American Society of Nephrology, Vol. 5, No. 5, 2010, pp. 929-935. doi:10.2215/CJN.09131209
|
[9]
|
X. Song, S. R. Long, W. D. Marder, S. D. Sullivan and J. Kallich, “The Impact of Methodological Approach on Cost Findings in Comparison of Epoetin Alfa with Darbepoetin Alfa,” Annals of Pharmacotherapy, Vol. 43, No. 7, 2009, pp. 1203-1210. doi:10.1345/aph.1L590
|